Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups
Open Access
- 1 September 1990
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 81 (3) , 373-379
- https://doi.org/10.1111/j.1365-2249.1990.tb05341.x
Abstract
We studied the immunologic correlates of disease activity and differences among subgroups of patients with idiopathic inflammatory myopathy by analysing phenotypic and activation marker expression on peripheral blood mononuclear cells (PBMC). Compared with controls, myositis patients with clinically active disease (n = 51) had significantly lower proportions of CD8‐ cells and higher proportions of PBMC that expressed DR. CD3‐ DR, CD14‐ DR, interlcukin‐2 receptors. and the late T cell activation markers CD26 and TLiSA1. TLiSA1 expression, a marker for cytotoxic differentiation, correlated significantly with both clinical activity indices and serum levels of muscle‐associated enzymes. In serial studies of seven patients, the proportion of PBMC expressing MHC class II antigen and late T cell activation markers decreased as myositis disease activity decreased, independent of type of therapy. Among the clinical subgroups, polymyositis (n= 21) and inclusion body myositis (n=21) were virtually indistinguishable; dcrmatomyositis patients (n= 19) showed decreased proportions of CD3+DR+ and TLiSA1+ cells, and increased proportions of CD20+ and CD20+ DR+ cells compared with the other two groups. Patients with autoantibodies to histidyl‐tRNA synthctasc (Jo‐1 antigen. n= 11) had significantly lower proportions of CD3+ andCD4+ cells, lower CD4/CD8 ratios, and higher proportions of DR+ cells expressing CD20, compared with patients without anti‐Jo‐1 antibodies. These findings support the concept that activated lymphocytes, especially cells undergoing anamnestic responses and cytotoxic differentiation, are important in the pathogenesis of idiopathic myositis. Moreover, taken together with other studies, these data suggest that groups of patients segregated by clinical or autoantibody status have different mechanisms of systemic immune activation and immunopathology.Keywords
This publication has 32 references indexed in Scilit:
- Expression of TLiSA1 on T cells from patients with rheumatoid arthritis and systemic lupus erythematosusClinical Immunology and Immunopathology, 1989
- Very late activation antigen on synovial fluid T cells from patients with rheumatoid arthritis and other rheumatic diseasesArthritis & Rheumatism, 1989
- Proliferative response of peripheral blood mononuclear cells to autologous and allogeneic muscle in patients with polymyositis/dermatomyositisArthritis & Rheumatism, 1989
- T lymphocytes compartmentalized on the epithelial surface of the lower respiratory tract express the very late activation antigen complex VLA-1Clinical Immunology and Immunopathology, 1988
- Microvascular Deposition of Complement Membrane Attack Complex in DermatomyositisNew England Journal of Medicine, 1986
- In Vivo Activated T Lymphocytes in the Peripheral Blood and Cerebrospinal Fluid of Patients with Multiple SclerosisNew England Journal of Medicine, 1985
- TLiSA1, a human T lineage-specific activation antigen involved in the differentiation of cytotoxic T lymphocytes and anomalous killer cells from their precursors.The Journal of Experimental Medicine, 1985
- Disturbance of regulatory lymphocyte subsets in polymyositisAnnals of Neurology, 1984
- T‐cell subsets in polymyositisAnnals of Neurology, 1983
- Rapid data collection, analysis, and graphics for flow microfluorometry instrumentationReview of Scientific Instruments, 1978